Potential therapy removes APOE and plaques from brain
Years before people start showing characteristic symptoms of Alzheimer’s disease, sticky plaques begin forming in their brains, damaging nearby cells. For decades, doctors have sought ways to clear out these plaques as a way to prevent or treat the disease.
The sticky clumps, known as amyloid plaques, are composed primarily of a brain protein called amyloid beta. But nestled within the plaques are small amounts of another Alzheimer’s protein: APOE. Now, researchers at Washington University School of Medicine have shown that an antibody not only targets APOE for removal but sweeps away plaques.
The findings, available March 26 in the Journal of Clinical Investigation, could lead to a way to halt the brain damage triggered by amyloid plaques while the disease is still in its early stages, perhaps before symptoms appear.
“Many people build up amyloid over many years, and the brain just can’t get rid of it,” said senior author David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology. “By removing plaques, if we start early enough, we may be able to stop the changes to the brain that result in forgetfulness, confusion and cognitive decline.”
Variants of the gene APOE are the single largest risk factor for Alzheimer’s disease. In earlier work, Holtzman and colleagues have shown that a DNA-based compound that targets APOE can lessen the injury caused by amyloid plaques.
But getting rid of the plaques likely would protect the brain better than blunting the plaques’ destructiveness. To find out whether the plaques could be removed, Holtzman, co-first authors Fan Liao, PhD, a postdoctoral researcher, and Aimin Li, PhD, a senior scientist, and colleagues focused on antibodies that recognize and bind to APOE. Once antibodies attach themselves to their APOE target, they attract the attention of roving immune cells, which carry both antibody and target off to be destroyed. The researchers reasoned that nearby amyloid might be cleared away along with APOE.
The researchers tested several antibodies that recognize human APOE in mice genetically predisposed to develop amyloid plaques. The APOE genes of the mice had been replaced with a human APOE gene. The antibodies were developed in collaboration with Denali Therapeutics.
For six weeks, the mice were given weekly injections of placebo or antibodies against APOE. Then, the researchers measured the amount of plaques in their brains. One antibody – called HAE-4 – cut the level of plaques by half.
Moreover, HAE-4 had no effect on APOE levels in the blood. APOE plays an important role in transporting fats and cholesterol in the body, so removing it from the bloodstream could create unwanted side effects. The failure of the antibody to lower levels of APOE in the blood was therefore a good sign. But it was also a mystery. Why did the antibody clear APOE from the brain but not the blood?
“It turns out that the APOE in the plaques has a different structure than the form of APOE found in the blood,” Holtzman said. “The HAE-4 antibody recognized only the form found attached to the plaques in the brain.”
No treatment exists to prevent or delay onset – or slow the trajectory – of Alzheimer’s disease. But a few antibodies that clear plaques by targeting amyloid beta are being evaluated in clinical trials. While such antibodies are promising, they sometimes come with the side effect of inflammation and swelling in the brain.
However, antibodies that target APOE may be successful at removing plaques in people and somewhat less likely to trigger a destructive immune response, Holtzman said.
“The anti-amyloid antibodies are going to be binding to most of the molecules that are in the plaque, but the anti-APOE antibody would target just a very small component of the plaque,” Holtzman said. “This means we may find less immune activation, and we might not see the unwelcome side effects.”
The researchers are planning further studies to determine whether similar antibodies are safe and might be effective enough to be used in people.
The Latest on: Alzheimer’s plaques
via Google News
The Latest on: Alzheimer’s plaques
The Menopause-Alzheimer’s Connection
on April 18, 2018 at 9:19 am
It stimulates neural activity and may help prevent the build up of plaques that are connected to the onset of Alzheimer’s disease. When estrogen levels decline, the female brain becomes much more vulnerable. To determine this, my colleagues and I used a ... […]
Why ‘Biomarkers’ Will Be Used to Detect Some Alzheimer’s Cases
on April 17, 2018 at 4:26 pm
According to the new guidelines, an Alzheimer’s disease diagnosis will now be based on three main biomarkers: the buildup of beta-amyloid proteins (plaques), tau proteins (tangles), and neurodegeneration. “The new definition is an attempt to better ... […]
New definition of Alzheimer’s changes how disease is researched
on April 17, 2018 at 9:25 am
So, in the new research framework, Alzheimer’s disease is not diagnosed based on symptoms. Instead, it is diagnosed by its neuropathology, referred to as plaques and tangles. This can be done at autopsy or using biomarkers when a person is still living. […]
Two is better than one to improve brain function in Alzheimer's disease mouse model
on April 16, 2018 at 10:32 am
"Amyloid-beta is a small protein that is abundant in the amyloid plaques that characterize Alzheimer's disease." All previous clinical trials designed to reduce the levels of amyloid-beta using one therapy at a time have had limited success. Jankowsky and ... […]
Medical Discovery News: Can Alzheimer’s be infectious?
on April 16, 2018 at 7:28 am
βA buildups in the brain are called plaques. It is not known if these βA plaques cause Alzheimer’s or are coincident with the disease. Nevertheless, the appearance of these plaques in the brain upon autopsy is the only way to definitively diagnose the ... […]
Here's Exactly How Many Nights of Bad Sleep You Can Get Before Raising Your Alzheimer's Risk
on April 16, 2018 at 5:31 am
These plaques interfere with the ability of brain cells to signal each other and are considered a hallmark of Alzheimer's. Proof of a problem In a study led by Ehsan Shokri-Kojori published in Proceedings of the National Academy of Sciences, researchers ... […]
Lack of Sleep May Be Linked to Beta-Amyloid Increase—A Risk Factor for Alzheimer’s Disease
on April 15, 2018 at 4:01 pm
In Alzheimer’s disease, beta-amyloid proteins clump together to form amyloid plaques, a hallmark of the disease. While acute sleep deprivation is known to elevate brain beta-amyloid levels in mice, less is known about the impact of sleep deprivation on ... […]
How the brain's 'immune memory' may lead to Alzheimer's
on April 14, 2018 at 12:03 am
This "memory" influences how the cells react to new stimuli and deal with toxic plaque in the brain, a marker of Alzheimer's disease. As the key player in the brain's immunity, microglia are dispatched to the site of infection or injury, where they fight ... […]
Alzheimer plaque affects different brain cells differently
on April 13, 2018 at 7:50 am
Amyloid beta, a protein linked with Alzheimer's disease, has different properties in different cell types in the brains of fruit flies. This is the conclusion of a study led by researchers at Linköping University in Sweden. While amyloid beta is highly ... […]
via Bing News